Kinarus
ExitedKinarus develops differentiated medicines in areas of stress related inflammatory processes based on cross disease area target assessment.
Kinarus has raised €73M across 2 funding rounds from 2 investors, most recently a Debt round in Aug 2022. Based in Basel, Switzerland; active in Healthtech. Acquired by Curatis in 2024. Data as of 28 Oct 2026.
Basel, Switzerlandwww.kinarus.com ↗
Total raised
€73M
€73,237,657
Funding rounds
2
Investors
2
distinct backers
Active since
2021-09
latest 2022-08
Funding by year
EUR raised per yearKinarus — funding by year — interactive chart.
Data table
| Kinarus — funding by year | |
|---|---|
| 2021 | €52M |
| 2022 | €21M |
Funding rounds
2 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2022-08-22 | Debt | €21M | YA II PN | View deal → |
| 2021-09-16 | Other | €52M | Global Emerging Markets | View deal → |
Exit
Type
merger
Date
Apr 2024
Value
—
Acquiror
Curatis (Switzerland)
Investors
2Related news
- Kinarus secures CHF20 million to accelerate clinical developmentstartupticker.ch · 2022-08
- Kinarus secures CHF 57 millionstartupticker.ch · 2021-09
- startupticker.ch
Similar companies
same sector or country- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
- CMR Surgical€1.5BUK · Healthtech
- Roivant Sciences€1.1BSwitzerland · Healthtech
- Neko Health€924MSweden · Healthtech
- Climeworks€919MSwitzerland · Cleantech
Global coverage: FundingData